Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, provides an overview of novel immune-based approaches in multiple myeloma. Existing immunotherapies such as CAR-T cells still suffer from high rates of relapse, and targeting other immune cells such as NK cells and myeloid suppressor cells are promising strategies. Analyzing the cell phenotype and MHC class I expression levels are additionally crucial to evaluate responses to cell therapies. Iberdomide and mezigdomide, both immunomodulatory compounds, have also shown to increase response rates in multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
